The dominance of the US, and its technology companies in particular, has become an accepted feature of global stock markets.

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

BBI Solutions Limited ("BBI"), global leader in the development and manufacture of IVD reagents, announces a CEO succession. After 7 years as ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Meta, Amazon Web Services, Novo Nordisk, xAI took top honors in Business Facilities’ 2024 Deal Of The Year Awards, ...

You deposit a lump sum or contribute monthly and acquire your very own slice of the world's starriest companies.